Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Abstract

Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.).

Keywords

Affiliated Institutions

• Pfizer (United States) US
• Brigham and Women's Hospital US
• University of Ulsan KR
• University of Tübingen DE
• The Netherlands Cancer Institute NL
• Georgetown Lombardi Comprehensive Cancer Center
• Dana-Farber Brigham Cancer Center US
• Osaka University Hospital JP
• The University of Texas MD Anderson Cancer Center US
• Pfizer (Italy) IT
• Royal Marsden NHS Foundation Trust GB
• Euromedic PL
• Université Claude Bernard Lyon 1 FR
• Centre Léon Bérard FR
• Cleveland Clinic US
• Macquarie University AU
• University of Glasgow GB
• Medical University of Vienna AT
• Jewish General Hospital CA
• Institut Gustave Roussy FR
• BC Cancer Agency CA
• Ulsan College KR
• Dana-Farber Cancer Institute US
• Russian Railways RU
• McGill University CA
• Beatson West of Scotland Cancer Centre GB
• Memorial Sloan Kettering Cancer Center US
• Comprehensive Cancer Center Vienna AT
• Asan Medical Center KR

Related Publications